These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28013106)

  • 1. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation.
    Gordon MJ; Tardi P; Loriaux MM; Spurgeon SE; Traer E; Kovacsovics T; Mayer LD; Tyner JW
    Leuk Res; 2017 Feb; 53():39-49. PubMed ID: 28013106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program.
    Carol H; Fan MM; Harasym TO; Boehm I; Mayer LD; Houghton P; Smith MA; Lock RB
    Pediatr Blood Cancer; 2015 Jan; 62(1):65-71. PubMed ID: 25203866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia.
    Cafaro A; Giannini MB; Silimbani P; Cangini D; Masini C; Ghelli Luserna Di Rorà A; Simonetti G; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):455-466. PubMed ID: 32955826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.
    Lancet JE; Cortes JE; Hogge DE; Tallman MS; Kovacsovics TJ; Damon LE; Komrokji R; Solomon SR; Kolitz JE; Cooper M; Yeager AM; Louie AC; Feldman EJ
    Blood; 2014 May; 123(21):3239-46. PubMed ID: 24687088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells.
    Kim HP; Gerhard B; Harasym TO; Mayer LD; Hogge DE
    Exp Hematol; 2011 Jul; 39(7):741-50. PubMed ID: 21530609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts.
    Lim WS; Tardi PG; Dos Santos N; Xie X; Fan M; Liboiron BD; Huang X; Harasym TO; Bermudes D; Mayer LD
    Leuk Res; 2010 Sep; 34(9):1214-23. PubMed ID: 20138667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.
    Mayer LD; Tardi P; Louie AC
    Int J Nanomedicine; 2019; 14():3819-3830. PubMed ID: 31213803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
    Usuki K; Miyamoto T; Yamauchi T; Ando K; Ogawa Y; Onozawa M; Yamauchi T; Kiyoi H; Yokota A; Ikezoe T; Katsuoka Y; Takada S; Aotsuka N; Morita Y; Ishikawa T; Asada N; Ota S; Dohi A; Morimoto K; Imai S; Kishimoto U; Akashi K; Miyazaki Y;
    Int J Hematol; 2024 Jun; 119(6):647-659. PubMed ID: 38532078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daunorubicin and Cytarabine Liposome in Newly Diagnosed Therapy-Related Acute Myeloid Leukemia (AML) or AML With Myelodysplasia-Related Changes.
    Kim M; Williams S
    Ann Pharmacother; 2018 Aug; 52(8):792-800. PubMed ID: 29532662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment.
    Nikanjam M; Capparelli EV; Lancet JE; Louie A; Schiller G
    Cancer Chemother Pharmacol; 2018 Jan; 81(1):171-178. PubMed ID: 29167924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine:daunorubicin formulation, in consolidation treatment against human leukemia xenografts.
    Lim WS; Tardi PG; Xie X; Fan M; Huang R; Ciofani T; Harasym TO; Mayer LD
    Leuk Lymphoma; 2010 Aug; 51(8):1536-42. PubMed ID: 20528246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Exposure-Response Analyses for CPX-351 in Patients With Hematologic Malignancies.
    Wang Q; Banerjee K; Vasilinin G; Marier JF; Gibbons JA
    J Clin Pharmacol; 2019 May; 59(5):748-762. PubMed ID: 30566230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin.
    Schittenhelm MM; Kampa KM; Yee KW; Heinrich MC
    Cell Cycle; 2009 Aug; 8(16):2621-30. PubMed ID: 19625780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review.
    Megías-Vericat JE; Martínez-Cuadrón D; Sanz MÁ; Poveda JL; Montesinos P
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):197-218. PubMed ID: 30672340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia.
    Feldman EJ; Kolitz JE; Trang JM; Liboiron BD; Swenson CE; Chiarella MT; Mayer LD; Louie AC; Lancet JE
    Leuk Res; 2012 Oct; 36(10):1283-9. PubMed ID: 22840315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia.
    Asghari H; Lancet J
    Leuk Lymphoma; 2020 Jun; 61(6):1305-1312. PubMed ID: 32037927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.
    Lin TL; Newell LF; Stuart RK; Michaelis LC; Rubenstein E; Pentikis HS; Callahan T; Alvarez D; Liboiron BD; Mayer LD; Wang Q; Banerjee K; Louie AC
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):163-173. PubMed ID: 31098682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence and clinical profiles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and CEBPA mutations in a cohort of patients with de novo acute myeloid leukemia from southwest China.
    Gou H; Zhou J; Ye Y; Hu X; Shang M; Zhang J; Zhao Z; Peng W; Zhou Y; Zhou Y; Song X; Lu X; Ying B
    Tumour Biol; 2016 Jun; 37(6):7357-70. PubMed ID: 26676635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients.
    Libura M; Giebel S; Piatkowska-Jakubas B; Pawelczyk M; Florek I; Matiakowska K; Jazwiec B; Borg K; Solarska I; Zawada M; Czekalska S; Libura J; Jakobczyk M; Karabin K; Paluszewska M; Calbecka M; Gajkowska-Kulik J; Gadomska G; Kielbinski M; Ejduk A; Kata D; Grosicki S; Wierzbowska A; Kyrcz-Krzemien S; Warzocha K; Kuliczkowski K; Skotnicki A; Holowiecki J; Jedrzejczak WW; Haus O
    Blood; 2016 Jan; 127(3):360-2. PubMed ID: 26567156
    [No Abstract]   [Full Text] [Related]  

  • 20. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.